Needham upgraded Amphastar (AMPH) (APMH) to Buy from Hold with a $36 price target. The company’s AMP-002 is an iron sucrose injection product that received FDA approval as an equivalent to Venofer, a $515M annual sales product, the analyst tells investors in a research note. The firm says the only downside to the approval is an equivalent generic product by Viatris (VTRS) was also approved. Needham cites valuation for the upgrade of Amphastar and believes AMP-002 sales should help the company at least meet growth expectations for 2025 and 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar upgraded to Buy from Hold at Needham
- Amphastar Pharmaceuticals Enters Strategic Licensing Agreement
- Cautious Hold Rating on Amphastar Pharmaceuticals Amid Uncertain Product Approvals and Flat Revenue Growth
- Amphastar price target lowered to $25 from $30 at Piper Sandler
- Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights